Abstracts tagged "autoantibodies"

Abstract Number: 1264 • 2014 ACR/ARHP Annual Meeting
Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis
Hidenaga Kawasumi¹, Takahisa Gono¹, Yasushi Kawaguchi¹, Yasuhiro Katsumata¹, Hisae Ichida¹, Akiko Tochimoto¹, Masanori Hanaoka¹, Yuko Okamoto¹, Sayuri Kataoka¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Half of all polymyositis (PM)/dermatomyositis (DM) patients suffer from muscle weakness after initial treatment. Therefore, many patients with PM/DM have trouble with daily living…
Abstract Number: 455 • 2014 ACR/ARHP Annual Meeting
Clinical and Tissue Specificity of Antibodies Against Carbamylated Proteins in Patients with Rheumatoid Arthritis
Antonio Gonzalez¹, Ariana Montes¹, Eva Perez-Pampin¹, Maria Dolores Boveda² and Juan J. Gomez-Reino^1,3, ¹Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Laboratorio Metabolopatias, Insitituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ³Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
Background/Purpose Antibodies against carbamylated proteins (CarP) are a new type of autoantibodies specific of patients with rheumatoid arthritis (RA) relative to healthy controls, but their…
Abstract Number: 2392 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibodies (anti-CarPA) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Marije K Verheul², Anne Barton^3,4, Tarnya Marshall⁵, Bo Fu⁶, René E.M. Toes⁷, Deborah PM Symmons^1,4, Leendert A. Trouw⁷ and Suzanne MM Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁶Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-CarPA have been shown to predict development of rheumatoid arthritis (RA) in patients with arthralgia. However, little is known about their association with disease…
Abstract Number: 1260 • 2014 ACR/ARHP Annual Meeting
The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease with Anti- Synthetase Antibodies
Yuji Hosono¹, Ran Nakashima², Yoshitaka Imura³, Naoichiro Yukawa², Hajime Yoshifuji², Takaki Nojima⁴, Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Interstitial lung disesases (ILD) is the most common cause of mortality in polymyosotis (PM) and dermatomyositis (DM). Cyclosporine had been reported to improve clinical…
Abstract Number: 454 • 2014 ACR/ARHP Annual Meeting
The Specificity of Anti-Carbamylated Protein Antibodies for Rheumatoid Arthritis in a Setting of Early Arthritis
Jing Shi, H.W. van Steenbergen, J. a. B. van Nies, E.W.Nivine Levarht, Annette H. M. van der Helm- van Mil, Tom W. J. Huizinga, René E.M. Toes and Leendert A. Trouw, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Anti-carbamylated protein (anti-CarP) antibodies have been described in rheumatoid arthritis (RA) and arthralgia patients [1;2] and occur in subsets of the anti-CCP2 positive and…
Abstract Number: 2085 • 2013 ACR/ARHP Annual Meeting
Identification Of Clinical Features and Risk Factors Associated With Calcinosis In Adult Patients With Dermatomyositis
Antonia Valenzuela¹, Lorinda Chung², Livia Casciola-Rosen³, Antony Rosen³ and David Fiorentino⁴, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Prior studies have estimated that 20% of adult dermatomyositis (DM) patients suffer from calcinosis. Although calcinosis is related to persistent disease activity, poor treatment…
Abstract Number: 1304 • 2013 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)
Jenny H. Humphreys¹, Suzanne M. Verstappen¹, Kimme L. Hyrich², Tarnya Marshall³, Anne Barton^4,5, René E.M. Toes⁶, Leendert A. Trouw⁶ and Deborah P. Symmons^4,7, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Autoantibodies against carbamylated proteins (anti-CarP) have been associated with more severe radiological damage in patients with rheumatoid arthritis (RA), including in a small subgroup…
Abstract Number: 28 • 2013 ACR/ARHP Annual Meeting
Differentiation, Activation, and Autoreactivity Of CD11c+ B Cells (ABCs)
Alice E. Wiedeman¹, Natalia V. Giltiay², Lena Tanaka³ and Keith B. Elkon³, ¹Immunology, University of Washington, Seattle, WA, ²Department of Immunology, Division of Rheumatology, University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Recently, a population of CD11c+ age-associated B cells (ABCs) was identified in normal aged female mice. These cells could be expanded following activation by…
Abstract Number: 2062 • 2013 ACR/ARHP Annual Meeting
Clinical Features and Outcome In Polymyositis Vs. Dermatomyositis Patients With The Anti-Jo-1 Autoantibody
Rohit Aggarwal¹, Diane Koontz², Zengbiao Qi³ and Chester V. Oddis⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The clinical characteristics of dermatomyositis (DM) patients possessing the anti-Jo-1 autoantibody (autoAb) are not well known. We analyzed the clinical features and prognosis of…
Abstract Number: 1288 • 2013 ACR/ARHP Annual Meeting
Development Of Antibodies Specific For Carbamylated Protein Precedes Disease Onset In Mice With Collagen-Induced Arthritis
Leendert A. Trouw¹, Bisheng Liu¹, Jing Shi¹, Diahann T.S.L. Jansen¹, Martin Hegen², Tom W.J. Huizinga¹, Jeroen N. Stoop¹ and René E. M. Toes¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pfizer, Cambridge, MA
Background/Purpose: Antibodies against citrullinated proteins are a characteristic of rheumatoid arthritis (RA). Recently, we demonstrated that autoantibodies recognizing homocitrulline containing proteins are present in sera…
Abstract Number: 26 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Directed Against Cell Surface Components In Autoimmune Disease Patients: Proposal Of a Novel ELISA For The Detection Of Anti-Endothelial Cell Antibodies
Keiji Miura¹, Ayako Kondo², Kazuo Takahashi², Daisuke Hirano², Yoshiyuki Hiki³, Shunji Yoshida², Yukio Yuzawa² and Yoshikazu Kurosawa³, ¹Institute for Comprehensive Medical Science, Fujita Health Universtiy, Toyoake, Japan, ²Fujita Health Universtiy School of Medicine, Toyoake, Japan, ³Fujita Health Universtiy, Toyoake, Japan
Background/Purpose: Sera from patients with systemic vasculitis or inflammatory conditions have been reported to contain antibodies that bind to endothelial cells (EC), i.e., AECA (anti-endothelial…
Abstract Number: 2065 • 2013 ACR/ARHP Annual Meeting
The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies
Xin Lu¹, Guochun Wang², Qinglin Peng³, Kai Yuan⁴ and Hanbo Yang⁵, ¹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, Beijing, China, ²Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ³Department of Rheumatology,, China-Japan Friendship Hospital, Beijing, China, ⁴Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ⁵Rheumatology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: To determine the sera levels of anti-NXP-2 antibodies and their clinical association in Chinese patients with idiopathic inflammatory myopathies(IIM). Methods: Sera from 198 Chinese…
Abstract Number: 1099 • 2013 ACR/ARHP Annual Meeting
IgG Autoantibodies Against p29ING4 In Early-Stage Type I Complex Regional Pain Syndrome (CRPS) and In Other Inflammatory Diseases Involving The Joints
Niklas T. Baerlecken¹, Torsten Witte², Reinhold E. Schmidt¹, Christina Lansche¹, Michael Bernateck³ and Nils Pursche⁴, ¹Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ²Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ³Anesthesiology, Pain Clinic, Medical University of Hannover, Hannover, Germany, ⁴Clinical Immunology and Rheumatology, Medical University of Hannover, Hannover, Germany
Background/Purpose: Complex regional pain syndrome (CRPS, a.k.a. RSD) usually occurs after limb injury, especially fractures of the distal radius and elective hand surgery. Recent research…
Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Hao Li¹, Hui-Chen Hsu², Qi Wu³, Jun Li³, PingAr Yang³, Yang-Xin Fu⁴ and John D. Mountz⁵, ¹Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VA Medical Center, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pathology, The University of Chicago, Chicago, IL, ⁵Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…
Abstract Number: 2861 • 2013 ACR/ARHP Annual Meeting
Accounting For Parental Load and Identification Of Multiple Risk Variants For Anti-Ro Congenital Heart Block Through High-Density Genotyping Of Immune-Related Loci
Robert M. Clancy¹, Jill P. Buyon², Nathalie Costedoat-Chalumeau³, Antonio Brucato⁴, Kateri Levesque⁵, Véronique Ramoni⁶, Miranda C. Marion⁷, Mary Comeau⁸, Satria Sajuthi⁹, Paula S. Ramos¹⁰, Robert P. Kimberly¹¹, Timothy D. Howard¹² and Carl D. Langefeld¹³, ¹Medicine, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Internal Medicine, Hopital Cochin, Paris, France, ⁴Internal Medicine, USC Internal Medicine, Ospedali Riuniti, Bergamo, Italy, ⁵Medicine Interne, Hopital Cochin, Paris, France, ⁶Rheumatology, Rheumatology University of Pavia, Pavia, Italy, ⁷Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, ⁸Wake Forest University Health Sciences, Winston-Salem, NC, ⁹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁰Department of Medicine, Medical University of South Carolina, Charleston, SC, ¹¹Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹²Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, ¹³Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC
Background/Purpose: Anti-Ro associated congenital heart block (CHB) exhibits a 33% concordance rate in monozygotic twins, 17.5% recurrence of disease and a high sibling risk ratio…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.